Sheila Gujrathi Buys 130,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sheila Gujrathi bought 130,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were bought at an average cost of $2.31 per share, with a total value of $300,300.00. Following the transaction, the director now directly owns 130,000 shares of the company’s stock, valued at approximately $300,300. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ventyx Biosciences Trading Up 2.6 %

NASDAQ VTYX traded up $0.06 on Thursday, hitting $2.33. 1,299,879 shares of the company’s stock were exchanged, compared to its average volume of 2,038,414. The stock has a 50-day moving average of $2.29 and a 200-day moving average of $2.33. The stock has a market cap of $164.76 million, a price-to-earnings ratio of -0.99 and a beta of 0.48. Ventyx Biosciences, Inc. has a 52 week low of $1.67 and a 52 week high of $11.48.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in VTYX. Palumbo Wealth Management LLC bought a new position in shares of Ventyx Biosciences during the third quarter valued at $26,000. China Universal Asset Management Co. Ltd. grew its position in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Ventyx Biosciences in the second quarter valued at about $32,000. Intech Investment Management LLC acquired a new position in shares of Ventyx Biosciences in the third quarter worth approximately $42,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on VTYX shares. Oppenheimer reissued an “outperform” rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.